RLMD
Relmada Therapeutics, Inc. · Healthcare
Director Paul Edward Kelly sold $179K of Relmada Therapeutics, Inc.
Sold$178,551
$35.71Price
5,000Shares
−3%Stake
What RLMD did after the filing
- The stock from Thu, Mar 11 close, $35.93
- +2.5%
- S&P 500, same days
- +6.2%
Measured over 30 trading days, to the Apr 23 close.
Traded Tue, Mar 9. Filed Thu, Mar 11, 12:50 PM ET, during the session. Returns use the Mar 11 close and the Apr 23 close. Not investment advice.